

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: SOPPET, et al.

Application Serial No.: To be assigned

Art Unit: To be assigned

Filed: Concurrently herewith

Examiner: To be assigned

For: G-Protein Parathyroid Hormone  
Receptor HLTGDG74

Atty. Docket No.: PF201D2



**INFORMATION DISCLOSURE STATEMENT**  
**PURSUANT TO 37 C.F.R. § 1.56**

Assistant Commissioner for Patents  
Washington, D.C. 20231

S I R:

In accordance with the duty of disclosure imposed by 37 C.F.R. § 1.56 to inform the Patent and Trademark Office of all references coming to the attention of each individual associated with the filing or prosecution of the subject application, which are or may be material to the patentability of a claim of the subject application, Attorneys for Applicants hereby direct the Examiner's attention to references AA-AN listed on the attached Form PTO/SB/08.

Copies of references AA-AN were submitted by Applicants or cited by the Examiner in connection with U.S. Patent Application Serial No. No. 09/236,468, filed January 25, 1999, or in connection with U.S. Patent Application Serial No. 08/468,011, filed June 6, 1995, to which the instant application claims priority under 35 U.S.C. § 120. Pursuant to 37 C.F.R. § 1.98(d), the Examiner is respectfully directed to the files of the above-listed applications for copies of references AA-AN.

Identification of the listed references is not to be construed an admission of any individual associated with the filing or prosecution of the subject application that such references are available as "prior art" against the subject application. Furthermore, Applicants do not waive any rights to appropriate action to establish patentability over any of the listed documents should they be applied as references against the claims of the subject application.

The above information is presented so that the Patent and Trademark Office can determine any materiality thereof to the claimed invention. See 37 C.F.R. 1.104(a) concerning the PTO duty to consider and use any such information. It is respectfully requested that the information be considered during the prosecution of this application.

Applicants respectfully request that the Examiner review the listed references and that the references be made of record in the file history of the application.

Pursuant to 37 C.F.R. § 1.97(b), since this information disclosure statement is being filed concurrently with the instant application, no fee is due in connection herewith. However, should the Patent Office determine otherwise, please charge the required fee to Human Genome Sciences, Inc., deposit account no. 08-3425.

Respectfully submitted,

Date: NOVEMBER 30, 2001

  
Janet M. Martineau (Reg. No. 46,903)  
Attorney for Applicants

**Human Genome Sciences, Inc.**  
9410 Key West Avenue  
Rockville, Maryland 20850  
Telephone: (301) 315-2723

KKH/JMM/DS/lcc

+

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
<h2 style="margin: 0;">INFORMATION DISCLOSURE STATEMENT BY APPLICANT</h2> <p style="margin: 5px 0 0 0;">(use as many sheets as necessary)</p>					
Sheet	1	of	3	Application Number	Unassigned
				Filing Date	Concurrently Herewith
				First Named Inventor	SOPPET, Daniel
				Group Art Unit	Unassigned
				Examiner Name	Unassigned
				Attorney Docket Number	PF201D2

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code <sup>2</sup> (if known)			

[illegible]

OTHER REFERENCES - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
	AA	USDIN, <i>et al.</i> , "Identification and Functional Expression of a Receptor Selectively Recognizing Parathyroid Hormone, the PTH2 Receptor", <i>The Journal of Biological Chemistry</i> , 270:(26):15455-15458(1995).	
	AB	ABO-SAMRA, et al., "Structure, Function, and Expression of the Receptor for Parathyroid Hormone and Parathyroid Hormone-Related Peptide", <i>Advances in Nephrology</i> , 23:247-264(1994).	
	AC	JUPPNER, MD, Harald., "Molecular cloning and characterization of a parathyroid hormone/parathyroid hormone-related peptide receptor: a member of an ancient family of G protein-coupled receptors", <i>Current Opinion in Nephrology and Hypertension</i> , 3:371-378(1994).	
	AD	MUFF, <i>et al.</i> , "Parathyroid Hormone and Parathyroid Hormone-related Protein Receptor Update", <i>Molecular &amp; Cellular Endocrinology</i> , 100:35-38(1994).	
	AE	MEYERHOF, <i>et al.</i> , "Molecular cloning of a novel putative G-protein coupled receptor expressed during rat spermiogenesis", <i>FEBS Letters</i> , 284(2):155-160(1991)	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIP Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.**

Please type a plus sign (+) inside this box



PTO/SB/08 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				Application Number	Unassigned
				Filing Date	Concurrently Herewith
				First Named Inventor	SOPPET, Daniel
				Group Art Unit	Unassigned
				Examiner Name	Unassigned
Sheet	2	of	3	Attorney Docket Number	PF201D2

U.S. PATENT DOCUMENTS						
Examiner Initials	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code <sup>2</sup> (if known)			

FOREIGN PATENT DOCUMENTS							
Examiner Initials	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)			

OTHER REFERENCES - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	
	AF	EVA, <i>et al.</i> , "Molecular cloning of a novel G protein-coupled receptor that may belong to the neuropeptide receptor family", <i>FEBS Letters</i> , 271(1-2):81-84(1990).	
	AG	HLA, <i>et al.</i> , "An Abundant Transcript Induced in Differentiating Human Endothelial Cells Encodes a Polypeptide with Structural Similarities to G-protein-coupled Receptors", <i>The Journal of Biological Chemistry</i> , 265(16):9308-9313(1990).	
	AH	ROSS, <i>et al.</i> , "RTA, a candidate G protein-coupled receptor: Cloning, sequencing, and tissue distribution", <i>Biochemistry</i> , 87:3052-3056(1990).	
	AI	LIBERT, <i>et al.</i> , "Selective Amplification and Cloning of Four New Members of the G Protein-Coupled Receptor Family", <i>Science</i> , 244:569-572(1989).	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIP Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → +

PTO/SB/08 (08-00)  
Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete if Known</b>	
Sheet		3	of	3	Application Number Unassigned
					Filing Date Concurrently Herewith
					First Named Inventor SOPPET, Daniel
					Group Art Unit Unassigned
					Examiner Name Unassigned
					Attorney Docket Number PF201D2

U.S. PATENT DOCUMENTS						
Examiner Initials <sup>1</sup>	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code <sup>2</sup> (if known)			

FOREIGN PATENT DOCUMENTS							
Examiner Initials <sup>1</sup>	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)			

OTHER REFERENCES - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials <sup>1</sup>	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	
	AJ	JUPPNER, <i>et al.</i> , "Opossum parathyroid hormone receptor mRNA, complete cds.", <i>GenBank Accession No. M74445</i> (27-Apr-1993)	T <sup>6</sup>
	AK	USDIN, <i>et al.</i> , "Human PTH2 parathyroid hormone receptor mRNA, complete cds.", <i>GenBank Accession No. U25128</i> , (07-Jul-1995)	
	AL	BLOECKER, <i>et al.</i> , "DKFZp434P0227_r1 434 (synonym: htes3) Homo sapiens cDNA clone DKFZp434P0227 5', mRNA sequence", <i>GenBank Accession No. AL043796</i> , (29-Feb-2000)	
	AM	ABOU-SAMRA, <i>et al.</i> , "Opossum kidney PTH/PTHrP receptor", <i>GeneSeq Accession No. R92276</i> (18-May-1996)	
	AN	ABOU-SAMRA, <i>et al.</i> , "Human kidney PTH/PTHrP receptor", <i>GeneSeq Accession No. R92278</i> (18-May-1996)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIP Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.